๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Surrogate endpoint biomarkers in chemopreventive agent development

Book ID
117659553
Publisher
Elsevier Science
Year
2002
Tongue
English
Weight
121 KB
Volume
38
Category
Article
ISSN
0959-8049

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Intraepithelial neoplasia, surrogate end
Intraepithelial neoplasia, surrogate endpoint biomarkers, and cancer chemoprevention
โœ Dr. Charles W. Boone; Gary J. Kelloff ๐Ÿ“‚ Article ๐Ÿ“… 1993 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 930 KB

Neoplasia is a progression of molecular, cellular, and tissue changes starting with a critical cell mutation and advancing by clonal evolution, involving further multiple mutations and expanding mutated clones. This process is characterized by five general stages: latency, focal growth of normal-app

Cervical cancer chemoprevention, vaccine
Cervical cancer chemoprevention, vaccines, and surrogate endpoint biomarkers
โœ Michele Follen; Frank L. Meyskens Jr.; Ronald D. Alvarez; Joan L. Walker; Maria ๐Ÿ“‚ Article ๐Ÿ“… 2003 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 883 KB

At the Second International Conference on Cervical Cancer, held April 11-14, 2002, experts in cervical cancer prevention, detection, and treatment reviewed the need for more research in chemoprevention, including prophylactic and therapeutic vaccines, immunomodulators, peptides, and surrogate endpoi

A phase II chemoprevention trial design
A phase II chemoprevention trial design to identify surrogate surrogate endpoint biomarkers in breast cancer
โœ Kapil Dhingra ๐Ÿ“‚ Article ๐Ÿ“… 1995 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 434 KB

Surrogate biomarkers for risk assessment and efficacy of potential chemopreventive agents are needed to improve the efficiency and reduce the cost of conducting chemoprevention trials. In addition to criteria of sensitivity, specificity, quantifiability, and reproducibility applicable to most potent